Food and Insulin Effect on QT/QTC Interval of ECG

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-07-31

Study Completion Date

2011-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Moxifloxacin is routinely used as a probe to confirm assay sensitivity in thorough electrocardiogram (ECG) studies. It has been shown that a meal shortens the QT interval, which may affect pharmacokinetics (PK) and/or pharmacodynamics (PD) of the study drug. However, there is no published data clarifying this issue. There is also a paucity of data investigating ethnic differences of the effects of medicines on QTc.

The aims of the study were to compare the effect of different food contents to placebo on the changes in ECG and to demonstrate the effect of insulin, C-peptide and glucose on the ECG. This was done by giving different treatments on separate days, which included intravenous insulin, a high carbohydrate breakfast \[\>70%\], and a calorie reduced low carbohydrate American FDA standard breakfast. Moxifloxacin 400 mg was used as a positive control and was given with and without food to Caucasian and Japanese volunteers to investigate racial differences.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study Evaluating the Effect of a Single-dose Oral Administration of Nemonoxacin Capsule on QTc Intervals and Heart Rhythms of Healthy Subjects and the Influence of Food Intake on QTc Intervals and Pharmacokinetic Characteristics

NCT03362853

Healthy Volunteers

COMPLETED PHASE1

A Study to Investigate the Effect of PH-797804 on QTc Interval

NCT01862887

Healthy

COMPLETED PHASE1

A Study to Evaluate the PF-06700841 Effect on QTc Interval in Healthy Volunteers

NCT03656952

Healthy

COMPLETED PHASE1

Effect of Food on the Pharmacokinetics of TEW-7197 in Healthy Subjects

NCT03704675

Healthy Volunteers

COMPLETED PHASE1

Food Effect Study of HSK47388 in Healthy Subjects

NCT07192692

Pharmaceutical Preparations Health Adult Subjects

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study was initially performed in 24 healthy Caucasian and Japanese volunteers with an option to increase the sample size to up to 54 volunteers. The decision to increase the sample size to 32 was based on the standard deviation of the ECG intervals observed in the first 24 volunteers. This analysis was performed by an independent statistician under blinded conditions.

Each volunteer participated in 2 periods. Each period consisted of 1 baseline day (D-1) followed by 3 study days (D1 - D3) when the various food effect and drug treatments or placebo were administered. All volunteers received all treatments. Moxifloxacin was always given on D3 to prevent any carryover effect and there was a minimum washout period of 3 days in between the 2 periods.

How well the treatments (insulin/glucose, high carbohydrate breakfast, calorie reduced breakfast and moxifloxacin) were tolerated by the volunteers was assessed and any side effects noted.

We compared the effects of the various treatments between Caucasian and Japanese volunteers.

Moxifloxacin and placebo were given to volunteers by mouth, i.e. they were asked to swallow them with water. The different types of breakfast were provided which volunteers were asked to eat. Insulin and glucose were administered intravenously (Insulin/glucose clamp). Hence, the study was performed as an open-label design.

This study was conducted as a single site study at Richmond Pharmacology/ St George's University of London.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Effects of Different Meals on the QT/QTc Interval Insulin and Oral Hypoglycemic [Antidiabetic] Drugs Causing Adverse Effects in Therapeutic Use C-Peptide Effects on the QT/QTc Interval Moxifloxacin ECG Profile in Fed and Fasted State Japanese vs. Caucasian TQT Comparison

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Moxifloxacin 400 mg fasted

Moxifloxacin 400 mg fasted was administered on Day 3. For Day 1 and 2, there were 4 different sequences: Placebo and Insulin Clamp; Insulin Clamp and Continental breakfast; Continental breakfast and FDA breakfast; FDA breakfast and Placebo. Additionally, Caucasian vs Japanese subjects were analysed.

Group Type ACTIVE_COMPARATOR

Moxifloxacin 400 mg fasted

Intervention Type DRUG

Subjects receiving drug (400 mg moxifloxacin),having fasted overnight for 10 hours.

This is the standard probe for the assessment of assay sensitivity in Thorough QT (TQT) studies.

FDA breakfast

Intervention Type OTHER

Calorie reduced FDA standard breakfast (58% fat, low carbohydrates)- On the assumption that increases in C-peptide levels are responsible for the QTc shortening observed after a meal, a lesser effect on QTc compared to a carbohydrate rich breakfast should be observed.

Continental breakfast

Intervention Type OTHER

High carbohydrate breakfast (\>70% carbohydrates)- On the assumption that increases in C-peptide levels are responsible for the QTc shortening observed after a meal, a greater effect on QTc compared to a low carbohydrate breakfast (FDA standard breakfast) should be observed.

Insulin Clamp

Intervention Type PROCEDURE

A euglycaemic/hyperinsulinaemic clamp, (DeFronzo, 1979) involves acutely raising the plasma insulin levels to a steady state and maintaining a state of euglycaemia with a glucose infusion, thereby effectively stopping endogenous insulin and C-peptide release. This technique will confirm whether hyperinsulinaemia has any effect on the QT/QTc interval.

Placebo

Intervention Type DRUG

Comparison of different meals effect on Moxifloxacin PK profile

Moxifloxacin 400 mg fed

Moxifloxacin 400 mg fed was administered on Day 3 after Continental breakfast. For Day 1 and 2, there were 4 different sequences: Placebo and Insulin Clamp; Insulin Clamp and Continental breakfast; Continental breakfast and FDA breakfast; FDA breakfast and Placebo.

Additionally, Caucasian vs Japanese subjects were analysed.

Group Type EXPERIMENTAL

FDA breakfast

Intervention Type OTHER

Calorie reduced FDA standard breakfast (58% fat, low carbohydrates)- On the assumption that increases in C-peptide levels are responsible for the QTc shortening observed after a meal, a lesser effect on QTc compared to a carbohydrate rich breakfast should be observed.

Continental breakfast

Intervention Type OTHER

High carbohydrate breakfast (\>70% carbohydrates)- On the assumption that increases in C-peptide levels are responsible for the QTc shortening observed after a meal, a greater effect on QTc compared to a low carbohydrate breakfast (FDA standard breakfast) should be observed.

Moxifloxacin 400 mg fed

Intervention Type DRUG

Currently, there is no published data showing the effects of a single 400 mg oral dose of moxifloxacin on the ECG/QT/QTc after food.

Insulin Clamp

Intervention Type PROCEDURE

A euglycaemic/hyperinsulinaemic clamp, (DeFronzo, 1979) involves acutely raising the plasma insulin levels to a steady state and maintaining a state of euglycaemia with a glucose infusion, thereby effectively stopping endogenous insulin and C-peptide release. This technique will confirm whether hyperinsulinaemia has any effect on the QT/QTc interval.

Placebo

Intervention Type DRUG

Comparison of different meals effect on Moxifloxacin PK profile

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Moxifloxacin 400 mg fasted

Subjects receiving drug (400 mg moxifloxacin),having fasted overnight for 10 hours.

This is the standard probe for the assessment of assay sensitivity in Thorough QT (TQT) studies.

Intervention Type DRUG

FDA breakfast

Calorie reduced FDA standard breakfast (58% fat, low carbohydrates)- On the assumption that increases in C-peptide levels are responsible for the QTc shortening observed after a meal, a lesser effect on QTc compared to a carbohydrate rich breakfast should be observed.

Intervention Type OTHER

Continental breakfast

High carbohydrate breakfast (\>70% carbohydrates)- On the assumption that increases in C-peptide levels are responsible for the QTc shortening observed after a meal, a greater effect on QTc compared to a low carbohydrate breakfast (FDA standard breakfast) should be observed.

Intervention Type OTHER

Moxifloxacin 400 mg fed

Currently, there is no published data showing the effects of a single 400 mg oral dose of moxifloxacin on the ECG/QT/QTc after food.

Intervention Type DRUG

Insulin Clamp

A euglycaemic/hyperinsulinaemic clamp, (DeFronzo, 1979) involves acutely raising the plasma insulin levels to a steady state and maintaining a state of euglycaemia with a glucose infusion, thereby effectively stopping endogenous insulin and C-peptide release. This technique will confirm whether hyperinsulinaemia has any effect on the QT/QTc interval.

Intervention Type PROCEDURE

Placebo

Comparison of different meals effect on Moxifloxacin PK profile

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Moxifloxacin Moxifloxacin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy male or female, 20 - 45 years old
2. Signed ICF
3. Japanese - a descendant of four Japanese grandparents, carrying a Japanese passport and has not been outside Japan for more than 5 years prior to screening
4. The Caucasian - light to brown skin pigmentation; straight to wavy or curly hair; indigenous to Europe, northern Africa, western Asia, and India. The study may also include Caucasians from North America, Australia and South Africa
5. No clinical findings on the physical examination
6. Body mass index (BMI) = 18 - 25 kg/m2, body weight at least 48 kg.
7. Systolic blood pressure 90-145 mmHg, diastolic blood pressure 40-90 mmHg, and heart rate 40-90 bpm
8. Triplicate 12 lead ECG without clinically relevant abnormalities
9. 24 hour 12 lead Holter ECG without clinically relevant abnormalities
10. Haematology, biochemistry and urinalysis within the normal range
11. Must agree to use acceptable methods of contraception

Exclusion Criteria

1. History or clinical evidence of any disease and/or existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism or excretion of the study drug
2. History of clinically significant syncope.
3. Family history of sudden death.
4. Family history of premature cardiovascular death.
5. Family history of congenital long QT syndrome or Brugada's syndrome.
6. History of arrhythmias and ischemic heart disease
7. Conditions predisposing to electrolyte imbalances (e.g. altered nutritional states, chronic vomiting, anorexia nervosa, bulimia nervosa).
8. Abnormal ECG in the standard 12-lead ECG and 24-hour 12 lead Holter ECG
9. Abnormal rhythm, conduction or morphology of resting ECG, such as:

* Sinus node dysfunction.
* Clinically significant PR (PQ) interval prolongation.
* Intermittent second or third degree AV block.
* Incomplete or complete bundle branch block.
* Abnormal T wave morphology.
* Prolonged QTcB \>450 msec or shortened QTcB \< 350 msec or family history of long QT syndrome.
10. Abnormal blood glucose result (blood glucose \>7.8mmol/l)
11. Significant family history of diabetes mellitus.
12. Significantly elevated fasting blood glucose level
13. Signs and/or symptoms of acute illness in the four-week period prior to screening.
14. Veins unsuitable for intravenous puncture or cannulation on either arm
15. Known hypersensitivity to any medicines administered in the trial.
16. Treatment with any prescribed medication during the 2 weeks prior to first baseline day.
17. Treatment with any over-the-counter (OTC) medications during the 2 weeks prior to first baseline day.
18. Treatment with vitamins and/or minerals within 48 hours prior to the first baseline day.
19. Treatment with another investigational drug within 4 weeks prior to dosing or having participated in more than 3 investigational drug studies within a year prior to dosing.
20. Positive urine drug screen (amphetamines, benzodiazepines, cocaine, cannabinoids, opiates, barbiturates and methadone) or the alcohol breath test
21. History or clinical evidence of alcoholism (regular weekly alcohol intake of more than 14 units if female and 21 units if male) or drug abuse (compulsive, repetitive and/or chronic use of drugs or other substances with or without problems related to their use and/or where stopping or a reduction in dose will lead to withdrawal symptoms)
22. Excessive caffeine consumption (≥800 mg per day)
23. Smoking within 3 months prior to screening
24. Loss of 250 mL or more blood within 3 months prior to screening.
25. Positive results from the hepatitis serology, except for vaccinated subjects.
26. Positive results from the HIV serology.
27. Any circumstances or conditions, which may affect full participation in the study or compliance with the protocol.
28. Legal incapacity or limited legal capacity.

Minimum Eligible Age

20 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes